$BRFH
BARFRESH FOOD GROUP INC.

2024 Q3 Form 10-Q Financial Statement

#000149315224032201 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $3.637M $1.464M
YoY Change 39.72% -3.11%
Cost Of Revenue $2.377M $955.0K
YoY Change 40.65% -7.91%
Gross Profit $1.260M $509.0K
YoY Change 38.01% 7.38%
Gross Profit Margin 34.64% 34.77%
Selling, General & Admin $1.695M $1.454M
YoY Change 32.94% 30.05%
% of Gross Profit 134.52% 285.66%
Research & Development $52.00K $17.00K
YoY Change 62.5% -51.43%
% of Gross Profit 4.13% 3.34%
Depreciation & Amortization $55.00K $56.00K
YoY Change -46.08% -35.63%
% of Gross Profit 4.37% 11.0%
Operating Expenses $1.760M $1.520M
YoY Change 26.71% 25.0%
Operating Profit -$500.0K -$1.011M
YoY Change 5.04% 36.25%
Interest Expense -$13.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$513.0K -$1.011M
YoY Change 6.88% 36.25%
Income Tax
% Of Pretax Income
Net Earnings -$513.0K -$1.011M
YoY Change 7.77% 36.25%
Net Earnings / Revenue -14.11% -69.06%
Basic Earnings Per Share -$0.03 -$0.07
Diluted Earnings Per Share -$0.03 -$0.07
COMMON SHARES
Basic Shares Outstanding 14.75M shares 14.72M shares
Diluted Shares Outstanding 14.74M shares 14.72M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $401.0K $383.0K
YoY Change -60.3% -59.77%
Cash & Equivalents $401.0K $383.0K
Short-Term Investments
Other Short-Term Assets $226.0K $122.0K
YoY Change 32.94% 23.23%
Inventory $770.0K $1.534M
Prepaid Expenses
Receivables $1.663M $671.0K
Other Receivables $30.00K $19.00K
Total Short-Term Assets $3.090M $2.729M
YoY Change -3.47% 9.55%
LONG-TERM ASSETS
Property, Plant & Equipment $390.0K $300.0K
YoY Change -19.92% -52.15%
Goodwill
YoY Change
Intangibles $194.0K $210.0K
YoY Change -24.81% -23.64%
Long-Term Investments
YoY Change
Other Assets $98.00K $92.00K
YoY Change 880.0% 1214.29%
Total Long-Term Assets $682.0K $602.0K
YoY Change -9.31% -33.77%
TOTAL ASSETS
Total Short-Term Assets $3.090M $2.729M
Total Long-Term Assets $682.0K $602.0K
Total Assets $3.772M $3.331M
YoY Change -4.58% -2.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.220M $843.0K
YoY Change -27.9% 8.77%
Accrued Expenses $270.0K $155.0K
YoY Change 17.9% -54.41%
Deferred Revenue
YoY Change
Short-Term Debt $86.00K $0.00
YoY Change
Long-Term Debt Due $95.00K
YoY Change
Total Short-Term Liabilities $2.218M $1.544M
YoY Change -16.62% -20.29%
LONG-TERM LIABILITIES
Long-Term Debt $151.0K $0.00
YoY Change
Other Long-Term Liabilities $111.0K
YoY Change
Total Long-Term Liabilities $151.0K $111.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.218M $1.544M
Total Long-Term Liabilities $151.0K $111.0K
Total Liabilities $2.369M $1.655M
YoY Change -10.94% -14.56%
SHAREHOLDERS EQUITY
Retained Earnings -$62.77M -$62.26M
YoY Change 4.45% 4.42%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.403M $1.676M
YoY Change
Total Liabilities & Shareholders Equity $3.772M $3.331M
YoY Change -4.58% -2.03%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$513.0K -$1.011M
YoY Change 7.77% 36.25%
Depreciation, Depletion And Amortization $55.00K $56.00K
YoY Change -46.08% -35.63%
Cash From Operating Activities $5.000K -$780.0K
YoY Change -91.67% -5.45%
INVESTING ACTIVITIES
Capital Expenditures $57.00K $4.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$57.00K -$4.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 5.000K -780.0K
Cash From Investing Activities -57.00K -4.000K
Cash From Financing Activities 70.00K 0.000
Net Change In Cash 18.00K -784.0K
YoY Change -70.0% -4.97%
FREE CASH FLOW
Cash From Operating Activities $5.000K -$780.0K
Capital Expenditures $57.00K $4.000K
Free Cash Flow -$52.00K -$784.0K
YoY Change -186.67% -4.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Depreciation And Amortization
DepreciationAndAmortization
196000 usd
us-gaap Operating Expenses
OperatingExpenses
2976000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-742000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1460000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
843000 usd
CY2024Q2 us-gaap Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current
AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent
499000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155000 usd
CY2024Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
47000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1544000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1655000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62256000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1676000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3331000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1464000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
usd
BRFH Amounts Included In Measurement Of Lease Liabilities
AmountsIncludedInMeasurementOfLeaseLiabilities
usd
us-gaap Notes Issued1
NotesIssued1
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
BRFH Acquisition Of Longterm Software License In Exchange For Contract Payable
AcquisitionOfLongtermSoftwareLicenseInExchangeForContractPayable
usd
BRFH Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards
ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1670000 usd
CY2023Q4 us-gaap Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current
AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent
499000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
85000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
53000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2307000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
111000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2307000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
400000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
23000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14723906 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14723906 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14420105 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14420105 shares
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63932000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63299000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60796000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2503000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4810000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1511000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4293000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3602000 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
955000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1037000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2614000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2273000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
509000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
474000 usd
us-gaap Gross Profit
GrossProfit
1679000 usd
us-gaap Gross Profit
GrossProfit
1329000 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
583000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
625000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1277000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1293000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
871000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
493000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1729000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1487000 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
66000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
98000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
133000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1520000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1216000 usd
us-gaap Operating Expenses
OperatingExpenses
3139000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1011000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1647000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14722020 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14722020 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13003000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13003000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14611000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14611000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12290000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12290000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Net Income Loss
NetIncomeLoss
-1460000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1647000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
517000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
211000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
205000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-150000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
236000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-141000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
7000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
320000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-78000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
22000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-756000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-759000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
120000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1549000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2049000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
65000 usd
BRFH Repurchases From Stock Compensation Program
RepurchasesFromStockCompensationProgram
20000 usd
BRFH Repurchases From Stock Compensation Program
RepurchasesFromStockCompensationProgram
18000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1508000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2067000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1891000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3019000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
383000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
952000 usd
BRFH Amounts Included In Measurement Of Lease Liabilities
AmountsIncludedInMeasurementOfLeaseLiabilities
20000 usd
us-gaap Notes Issued1
NotesIssued1
71000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
136000 usd
BRFH Acquisition Of Longterm Software License In Exchange For Contract Payable
AcquisitionOfLongtermSoftwareLicenseInExchangeForContractPayable
154000 usd
BRFH Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards
ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards
24000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_z2GhPckTEVKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zWrNsLVN7CWi">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zIKN4gRU7PJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_znUcYRdfJn8l">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentration in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_894_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zly21y85v1D9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zaMxiegv0yUl" style="display: none">Schedule of Contract Manufacturers Percentage of Finished Goods</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20240401__20240630_zjcQ9ibIUgT8" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230401__20230630_zNJyizb0w4N5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240630_zCB8bghacWWa" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230101__20230630_zqjyWB6UGWOh" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended June 30,</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the six months ended June 30,</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zWxDuoaK4jA" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-left: 0pt">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">45</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">56</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zMx8FHuRED6e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_ztZ5lucxlnu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ztkPYKPwMrOl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration risk percentage</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A2_zc9tSd2jfUj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2024Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2024Q2 BRFH Shipping And Storage Costs
ShippingAndStorageCosts
217000 usd
CY2023Q2 BRFH Shipping And Storage Costs
ShippingAndStorageCosts
252000 usd
BRFH Shipping And Storage Costs
ShippingAndStorageCosts
581000 usd
BRFH Shipping And Storage Costs
ShippingAndStorageCosts
562000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zsep7WGIl0p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z4OAwhYKP4Tc">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 presentation, namely stock-based compensation paid to the Company’s directors has been reclassified from stock and options issued for services and shares repurchased for employee tax withholding under the Company’s stock compensation program have been reclassified to financing activities in the consolidated statement of cash flows, with corresponding changes reflected in the statement of stockholders’ equity for the six months ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
28000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
28000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1506000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1186000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
1534000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1214000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2954000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2956000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2654000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2547000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
300000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
409000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
56000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
87000 usd
us-gaap Depreciation
Depreciation
113000 usd
us-gaap Depreciation
Depreciation
174000 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
6000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
5000 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
13000 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
10000 usd
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-03-31
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extended in a series of amendments through September 30, 2024.
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
20000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
20000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
40000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
40000 usd
CY2022 us-gaap Multiemployer Plan Increase In Employer Contribution Business Combination Percentage
MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage
0.52 pure
CY2021 us-gaap Multiemployer Plan Increase In Employer Contribution Business Combination Percentage
MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage
0.42 pure
CY2024Q1 us-gaap Convertible Debt
ConvertibleDebt
2000000 usd
us-gaap Debt Instrument Description
DebtInstrumentDescription
The debt was available to be drawn in 25% increments, maturing on the anniversary of the draw, bearing interest at 10% per annum for the term, regardless of earlier payment or conversion, and was mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”).
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
1390000 usd
CY2023Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1207000 usd
CY2023Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
820160 shares
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
470000 usd
CY2023Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
653000 usd
CY2023Q4 us-gaap Debt Instrument Periodic Payment Interest
DebtInstrumentPeriodicPaymentInterest
4000 usd
CY2023Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
495331 shares
CY2024Q1 us-gaap Convertible Debt
ConvertibleDebt
136000 usd
CY2024Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
124208 shares
CY2023Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
30000 usd
CY2024Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
71000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2933000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-18000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
24000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
8000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1647000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1463000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2503000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2503000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-20000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
517000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
136000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1460000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1676000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1676000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
122739 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.10
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
797000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
587091 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.50
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
229849 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.97
BRFH Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
71930 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.95
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
745010 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
531540 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.935 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.71
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1549000 usd
CY2024Q2 BRFH Working Capital
WorkingCapital
1185000 usd
CY2024Q2 us-gaap Cash
Cash
383000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
320000 usd

Files In Submission

Name View Source Status
0001493152-24-032201-index-headers.html Edgar Link pending
0001493152-24-032201-index.html Edgar Link pending
0001493152-24-032201.txt Edgar Link pending
0001493152-24-032201-xbrl.zip Edgar Link pending
brfh-20240630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
brfh-20240630_def.xml Edgar Link unprocessable
brfh-20240630_lab.xml Edgar Link unprocessable
brfh-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
brfh-20240630_cal.xml Edgar Link unprocessable